Autolus Therapeutics Plc ADR (AUTL) Stock Price, Quote & News

Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 3829 6230

Website: www.autolus.com

Address:

The Mediaworks, 191 Wood Lane White City, London, United Kingdom

Biotechs5454 May. 13 at 11:51 AM

$AUTL I wonder if autoimmune is where big pharma could see the big value here.

2 · Reply

Roadto1mio May. 12 at 7:53 PM

$AUTL

0 · Reply

Biotechs5454 May. 12 at 7:03 PM

$AUTL 13Fs soon. MAK and Armistice - very interested what they did, if anything.

0 · Reply

diggs24 May. 12 at 7:01 PM

$AUTL ADR fee hit yesterday.

0 · Reply

Michael_garic May. 12 at 4:18 PM

$AUTL Well no interest from buyers ahead of earnings. Usual games with short sellers/market makers/AI bots. Investors in "wait and see" or "show me the money" phase....The tension builds....

1 · Reply

gandolf63 May. 12 at 1:52 PM

$AUTL its very strange. in spite of their excellent promising pipeline they are treated as tho they just have one struggling product

1 · Reply

ADMAGuy May. 12 at 1:29 PM

$AUTL I think they will have significant cash burn may Around $70 million net loss. May raise 2026 revenue guidance to around $150 million . May have nothing to say until end of Q3 with new data .

0 · Reply

Michael_garic May. 12 at 11:59 AM

$AUTL What to look for in Thursday's earnings call: AUCATZYL Q1 net product revenue/EPS vs. ~$26M consensus/(0.29) Center activations — How many new sites are live and treating patients? Gross margin progress — Any early improvement? 2026 guidance reaffirmation — Any color on confidence in the $120–135M target? Cash burn / runway — Updates on the $300M+ cash position and restructuring savings. Pipeline / autoimmune updates — Any new data timelines or partnership news?

3 · Reply

gandolf63 May. 12 at 11:44 AM

$AUTL could this be the start of a new trajectory going up instead of down after these filings this week?

0 · Reply

Biotechs5454 May. 11 at 9:53 PM

$AUTL Just want double digits. Is that asking too much????

0 · Reply

Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026

2026-04-29T22:04:39.000Z - 13 days ago

Autolus Therapeutics to reduce workforce by approximately 13%

Apr 29, 2026, 4:05 PM EDT - 13 days ago

Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction

Apr 21, 2026, 4:10 PM EDT - 21 days ago

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 13, 2026, 10:15 AM EDT - 4 weeks ago

Autolus Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

2026-04-13T10:06:36.000Z - 4 weeks ago

Autolus Therapeutics files to sell 54.58M American Depositary Shares for holders

2026-04-13T10:06:09.000Z - 4 weeks ago

Autolus Therapeutics files $150M mixed securities shelf

Apr 8, 2026, 1:00 PM EDT - 4 weeks ago

Autolus Therapeutics Transcript: Status update

Apr 7, 2026, 7:00 AM EDT - 5 weeks ago

Autolus Therapeutics to Participate in Upcoming Investor Conferences

2026-03-31T11:07:21.000Z - 6 weeks ago

Autolus Therapeutics price target lowered to $10 from $12 at Mizuho

Mar 27, 2026, 8:30 AM EDT - 6 weeks ago

Autolus Therapeutics Earnings Call Transcript: Q4 2025

2026-03-27T11:36:34.000Z - 6 weeks ago

Autolus Therapeutics reports Q4 EPS (34c), consensus (43c)

2026-03-27T11:05:12.000Z - 6 weeks ago

Options Volatility and Implied Earnings Moves Today, March 27, 2026

CCL HUMA KOPN LGN TMC

Mar 27, 2026, 7:00 AM EDT - 6 weeks ago

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Mar 16, 2026, 4:10 PM EDT - 2 months ago

Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026

Mar 3, 2026, 11:10 AM EST - 2 months ago

Autolus Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-17T11:11:16.000Z - 3 months ago

Autolus Therapeutics initiated with a Buy at H.C. Wainwright

2026-02-13T11:43:09.000Z - 3 months ago

Autolus Therapeutics price target lowered to $8 from $11 at H.C. Wainwright

2026-02-04T14:01:01.000Z - 3 months ago

Autolus Therapeutics reports inducement grants under Nasdaq listing rule

2026-01-13T14:02:20.000Z - 4 months ago

Autolus Therapeutics price target lowered to $8 from $10 at Truist

2026-01-12T16:55:27.000Z - 4 months ago

Autolus Therapeutics price target lowered to $10 from $11 at Needham

2026-01-12T12:11:24.000Z - 4 months ago

Autolus Therapeutics sees Q4 AUCATZYL revenue of $24M

2026-01-12T12:11:07.000Z - 4 months ago

Autolus Therapeutics sees FY26 AUCATZYL revenue $120M-$135M

2026-01-12T12:10:09.000Z - 4 months ago

Autolus Therapeutics sees cash runway into 4Q27

Jan 12, 2026, 7:00 AM EST - 4 months ago

Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026

2026-01-06T14:15:14.000Z - 4 months ago

Autolus Therapeutics to evaluate automated manufacturing of AUCATZYL

Jan 6, 2026, 9:00 AM EST - 4 months ago

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform

Jan 6, 2026, 9:00 AM EST - 4 months ago

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform

2025-12-29T13:05:39.000Z - 4 months ago

Needham ups Autolus target, names top pick for 2026

$Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025$

Dec 8, 2025, 4:05 PM EST - 5 months ago

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025

Dec 8, 2025, 8:35 AM EST - 5 months ago

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

Dec 1, 2025, 7:00 AM EST - 5 months ago

Autolus Therapeutics Appoints Ryan Richardson to Board of Directors

$NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹$

Nov 25, 2025, 4:00 AM EST - 6 months ago

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

Nov 18, 2025, 7:30 AM EST - 6 months ago

Autolus Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 4:05 PM EST - 6 months ago

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 12, 2025, 8:30 AM EST - 6 months ago

Autolus Therapeutics Earnings Call Transcript: Q3 2025

Nov 12, 2025, 7:00 AM EST - 6 months ago

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Nov 3, 2025, 9:05 AM EST - 6 months ago

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

Oct 30, 2025, 7:00 AM EDT - 6 months ago

Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

Oct 27, 2025, 7:00 AM EDT - 7 months ago

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

Oct 20, 2025, 7:00 AM EDT - 7 months ago

Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

Sep 16, 2025, 8:05 AM EDT - 8 months ago

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

Aug 12, 2025, 8:30 AM EDT - 9 months ago

Autolus Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 9 months ago

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Jul 24, 2025, 7:30 AM EDT - 10 months ago

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

$Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)$

Jul 21, 2025, 7:00 AM EDT - 10 months ago

Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Jun 12, 2025, 2:00 AM EDT - 11 months ago

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

Jun 11, 2025, 1:20 PM EDT - 11 months ago

Autolus Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 3:10 PM EDT - 1 year ago

Autolus Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

$Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)$

May 23, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

May 14, 2025, 9:30 AM EDT - 1 year ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

May 8, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

$Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)$

Apr 25, 2025, 12:06 PM EDT - 1 year ago

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Apr 23, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Transcript: Status Update

Apr 22, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Apr 9, 2025, 9:30 AM EDT - 1 year ago

Autolus Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Mar 20, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Earnings Call Transcript: Q4 2024

Mar 20, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 12, 2025, 8:40 AM EDT - 1 year ago

Autolus Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 6, 2025, 7:00 AM EST - 1 year ago

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Jan 17, 2025, 7:00 AM EST - 1 year ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Dec 9, 2024, 7:30 PM EST - 1 year ago

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Nov 21, 2024, 8:00 AM EST - 1 year ago

Autolus Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Autolus Therapeutics Earnings Call Transcript: Q3 2024

Nov 11, 2024, 8:30 AM EST - 1 year ago

Autolus Therapeutics Transcript: FDA Announcement

$Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)$

Nov 8, 2024, 4:23 PM EST - 1 year ago

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Oct 28, 2024, 5:00 PM EDT - 1 year ago

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Earnings Call Transcript: Q2 2024

Jul 26, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

$Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress$

Jun 14, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

Jun 12, 2024, 2:40 PM EDT - 2 years ago

Autolus Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 7:30 AM EDT - 2 years ago

Autolus Therapeutics Transcript: Jefferies Global Healthcare Conference

Jun 1, 2024, 9:30 AM EDT - 2 years ago

Autolus Therapeutics Transcript: Status Update

May 31, 2024, 8:00 AM EDT - 2 years ago

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

May 17, 2024, 8:30 AM EDT - 2 years ago

Autolus Therapeutics Earnings Call Transcript: Q1 2024

May 17, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Apr 24, 2024, 10:00 AM EDT - 2 years ago

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

Apr 23, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Apr 11, 2024, 9:30 AM EDT - 2 years ago

Autolus Therapeutics Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics Announces Changes to its Board of Directors

Mar 14, 2024, 9:00 AM EDT - 2 years ago

Autolus Therapeutics Earnings Call Transcript: Q4 2023

Mar 14, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Mar 12, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

Feb 29, 2024, 7:00 AM EST - 2 years ago

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

Feb 8, 2024, 7:00 AM EST - 2 years ago

Autolus Announces Pricing of Underwritten Offering

Feb 8, 2024, 5:45 AM EST - 2 years ago

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

Biotechs5454 May. 13 at 11:51 AM

$AUTL I wonder if autoimmune is where big pharma could see the big value here.

2 · Reply

Roadto1mio May. 12 at 7:53 PM

$AUTL

0 · Reply

Biotechs5454 May. 12 at 7:03 PM

$AUTL 13Fs soon. MAK and Armistice - very interested what they did, if anything.

0 · Reply

diggs24 May. 12 at 7:01 PM

$AUTL ADR fee hit yesterday.

0 · Reply

Michael_garic May. 12 at 4:18 PM

$AUTL Well no interest from buyers ahead of earnings. Usual games with short sellers/market makers/AI bots. Investors in "wait and see" or "show me the money" phase....The tension builds....

1 · Reply

gandolf63 May. 12 at 1:52 PM

$AUTL its very strange. in spite of their excellent promising pipeline they are treated as tho they just have one struggling product

1 · Reply

ADMAGuy May. 12 at 1:29 PM

$AUTL I think they will have significant cash burn may Around $70 million net loss. May raise 2026 revenue guidance to around $150 million . May have nothing to say until end of Q3 with new data .

0 · Reply

Michael_garic May. 12 at 11:59 AM

3 · Reply

gandolf63 May. 12 at 11:44 AM

$AUTL could this be the start of a new trajectory going up instead of down after these filings this week?

0 · Reply

Biotechs5454 May. 11 at 9:53 PM

$AUTL Just want double digits. Is that asking too much????

0 · Reply

TricksterT May. 11 at 7:33 PM

$AUTL struggling going into earnings. Be cautious and do not bet the house! Holding some.

0 · Reply

AshvsEvilDead May. 11 at 7:16 PM

$AUTL added a little more here. Just think the time is coming for this beaten down co. Valuation depressed. The tech is hot, it’s a proven modality, and there is an increased need. Market is growing substantially.

0 · Reply

JcoalX May. 11 at 1:28 PM

$AUTL quite the premarket swings. I'm sure there will be a bit of a selloff in the market given last weeks run. I just hope this little baby hangs on!

0 · Reply

Michael_garic May. 11 at 12:56 PM

$AUTL This is a great story...should give a lot of visibility to the CAR T world.

0 · Reply

Michael_garic May. 11 at 12:50 PM

$AUTL This week will give us a great indication of not only how AUTL is performing towards the goal of positive margins and market share but we will also see which institutions bought/sold/held AUTL shares. Friday, May 15 is the deadline for the institutions to disclose their holdings via 13F and 13G. AUTL Q1 earnings report on Thursday, May 14. AUTL webcast link for 2026 Q1 earnings call: https://edge.media-server.com/mmc/p/ow2td3vg/

0 · Reply

NANANANANANANAN May. 10 at 1:45 PM

$AUTL https://www.theguardian.com/society/2026/may/10/cancer-treatment-car-t-cell-therapy-sam-neill

0 · Reply

alexpitti May. 10 at 5:36 AM

i know this a random ass comparison, but how does $AUTL have a higher valuation than delcath, when delcath has mid 80s gross margin and autolus is trying to get to postive??? $DCTH and autolus both can be platforms with new data in 2027/2028, but autolus is rapidly running out of cash and delcath is literally buying back shares

1 · Reply

gandolf63 May. 9 at 2:35 PM

$AUTL

2 · Reply

gandolf63 May. 8 at 10:53 PM

$AUTL its not a slam dunk yet for in vivo. This is a good article that explains the challanges https://pmc.ncbi.nlm.nih.gov/articles/PMC13096480/ “Thus, in vivo-generated CAR cells confront a dual challenge: they lack the exogenous cytokine and co-stimulatory support available in vitro, while simultaneously facing inhibitory pressures from the pathological microenvironment—be it tumor-related or autoimmunity-driven. Together, these factors lead to limited expansion, reduced survival, insufficient memory subset formation, and impaired resistance to exhaustion, ultimately compromising therapeutic durability and efficacy “

1 · Reply

gandolf63 May. 8 at 5:38 PM

$AUTL seems like scam street has ignored their entire pipeline in determining share price

3 · Reply

Michael_garic May. 8 at 3:21 PM

$AUTL Tecartus is used for both Mantle Cell and B ALL indications. Estimated B ALL is 20% - 40% of total sales. AUTL only competes in B ALL, while majority of Tecartus is for MCL. This would indicate to me that AUTL is probably getting most of the B ALL business.

0 · Reply

MorganHoratio May. 8 at 1:24 PM

Google just released its updated 13F filing which shows all the stocks it owned as of the end of Q1: $ARM - 1,960,784 shares $ASTS - 8,943,486 $AUTL - 698,262 $BEAM - 321,604 $BBIO - 2,823,126 Google's Q1 13F is a masterclass in Space, Silicon, and AI Bio! The standout is definitely the 8.9M share stake in $ASTS. Despite the looming SpaceX IPO, Google is doubling down on this "Space-based Cell Tower"—a clear play for global Gemini AI dominance. $ARM remains the bedrock of its custom silicon (Axion) strategy, while $BEAM and $BBIO highlight a massive pivot into AI-driven drug discovery. Do you think $ASTS is Google's ultimate strategic hedge against Starlink in 2026? Which of these deep-tech plays are you adding to your watchlist?

1 · Reply

Market Cap	420.51M
Revenue (ttm)	75.39M
Net Income (ttm)	-287.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-381.39%
Debt to Equity Ratio	0.00

Volume	1,093,800
Avg Vol	1,560,158
Day's Range	N/A - N/A
Shares Out	266.14M
Stochastic %K	57%
Beta	1.93
Analysts	Strong Sell
Price Target	$8.79